Aegis Medical Innovations Announces FDA Approval of Clinical Trial
|Wednesday, 22 March 2017|
Aegis Medical Innovations Inc announced that it has received Investigational Device Exemption approval from the U.S. FDA to initiate a clinical trial in the U.S. for its medical device called the Sierra Ligation System (Sierra).
“Patients with AF are five times more likely to have a stroke, often due to clots that form in the left atrial appendage. We feel confident that the upcoming trial will show the Sierra procedure to be safe and effective for closing the LAA in patients suffering from AF”
"For many AF patients, anticoagulants are used to reduce the risk of stroke. One of the downsides of these drugs is that they can result in life-threatening bleeding. Aegis has developed a minimally invasive, non-vascular LAA closure device, that is designed to protect the patient from AF-related stroke without taking blood thinners,” said Vivek Reddy, MD, Mount Sinai Cardiovascular Disease Specialist. “In contrast to vascular treatments, this non-vascular approach does not implant a device inside the heart that might migrate or cause clots in the LAA, thus potentially improving patient safety.”
“Patients with AF are five times more likely to have a stroke, often due to clots that form in the left atrial appendage. We feel confident that the upcoming trial will show the Sierra procedure to be safe and effective for closing the LAA in patients suffering from AF,” said Trevor McCaw, Aegis Founder and President.
The hospital approval process has begun for the trial to take place at Mount Sinai in New York, NY; Mayo Clinic, Rochester, MN; Houston Methodist Hospital, Houston, TX; and Pacific Heart Institution, Santa Monica, CA. The clinical trial start date in the U.S. is scheduled for May 2017.
“This study will confirm the safety of the Sierra device for patient use, and will lay a solid foundation for future efforts to demonstrate that Sierra can prevent stroke in AF patients and eliminate the need to take blood thinners for stroke prevention,” notes the Lead Study Principal Investigator, Dr. Sheldon Singh from Sunnybrook Health Sciences Centre in Toronto, Ontario.
The Sierra procedure closes off the LAA by placing a ligature around the base of the LAA and cinching it down with a lock. Closing off the LAA from circulation prevents clots from leaving the appendage, eliminating a potential source of future stroke. Sierra is expected to be one of the simplest, most economical and safest percutaneous procedure for LAA closure. Sierra also has the potential to reduce, and possibly eliminate AF altogether in some patients.
Click here to see a video demonstration of LAA closure using Sierra.
About Aegis Medical Innovations Inc.
|< Prev||Next >|
Technology and Analytics are the key elements playing important role in many aspects of the healthcare delivery system.
With this in mind, we introduce the latest edition of Hospital & Healthcare Management Magazine - Vol 5 Issue 4 your one-stop resource that hepls you stay up to date with the issues that matters the most.
|View Previous Issues:|
May'16 | Feb'16 | Aug'15 | Feb'15 | Aug'14 | Feb'14 | June'13 | Feb.'13 | Aug.'12 | Apr.'12 | Dec.'11 | Aug.'11 | >>
|Healthcare 2015: Win-win or lose-lose?|
|The Challenge of Securing Hard to Patch Servers in Health Care Environments|